A Study of LY3209590 in Participants With Type 1 Diabetes

• Status: Completed
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Participants must have a diagnosis of type 1 diabetes mellitus for at least 1 year

• Participants must have been using multiple daily injections without interruption for at least 3 months

• Participants must have HbA1c values of 5.6% to 9.5%, inclusive

• Participants must have a body mass index (BMI) of ≤35 kilograms per meter squared (kg/m²)

Exclusion Criteria:

• Have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months prior to study screening

• Have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening

• Have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)

• Have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease

• Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²

• Have active or untreated cancer

• Are receiving chronic (>14 days) systemic glucocorticoid therapy